7 results about "Scatchard plot" patented technology

Provided are a method and system for predicting an activation potency of agonist molecules on G Protein-Coupled Receptors (GPCRs). The method includes: blindly speculating complex structures formed by binding of a ligand to an activated receptor structure and an inactivated receptor structure, respectively, via global molecular docking; extracting an initial path enabling an inactivated complex structure to be activated to an activated complex structure based on an enhanced sampling algorithm; searching for a minimum free energy path closest to the initial path by applying an automatic path optimization algorithm; calculating a free energy distribution curve along the minimum free energy path by employing umbrella sampling and determining an energy barrier height and a free energy difference before and after activation, thereby determining the activation potency of the ligand structure on the GPCRs.

According to the present invention, a method is provided for determining kinetic parameters of a reaction between an analyte and a ligand attached to a test surface of a flow cell, the method comprising the steps of: (a) flowing a first volume of sample fluid (V1) containing the analyte through the test surface between a first time point (t1) and a second time point (t2); (b) flowing a first volume of buffer fluid (Vb1) without the analyte through the test surface between a third time point (t3) and a fourth time point (t4); (c) flowing a sample fluid (V2) containing at least a second volume of the analyte through the test surface between a fifth time point (t5) and a sixth time point (t6); (d) flowing a buffer fluid (Vb2) without the analyte through the test surface between a seventh time point (t7) and an eighth time point (t8); (e) measuring the binding of the analyte to the ligand on the test surface using a sensor to obtain a binding curve; and (f) using only a portion of the binding curve within a predefined time interval and excluding other portions of the binding curve to determine the kinetic parameters.

This invention discloses a competitive homogeneous immunoassay method based on upconversion nanoparticles. The method involves conjugating activated upconversion nanoparticles to an antigen; enriching and purifying the upconversion nanoparticle-antigen probe; mixing the donor with specific antibodies and free antigens at different concentration gradients, followed by an immunoassay; receptor labeling; and detecting the fluorescence intensity of the reaction solution. The concentration of the antigen in the sample to be tested is obtained from the curve of the change in free antigen concentration versus fluorescence intensity, or the concentration of the target analyte is obtained at the single-particle level by counting the quantitative changes in the immune complex. This invention effectively solves the problems of high background noise and low signal-to-background ratio in resonance energy transfer (RET). By labeling the formed semi-sandwich structure immune complexes using a receptor deposition method, receptors accumulate around the immune complexes, increasing the number of receptors and shortening the distance between the donor and receptor, significantly improving RET efficiency and signal strength, thereby enhancing the sensitivity of the competitive homogeneous immunoassay.

The invention relates to a method for the qualitative determination of peripherin, comprising the combining and incubating of a diluted sample with a first antibody conjugate comprising a first antibody bound to a solid phase and a second antibody conjugate comprising a biotinylated second antibody, the removal of the liquid phase and the initiation and measuring of a colour reaction. The invention also relates to a quantification of peripherin in a sample by means of a calibration curve, to the creation of a calibration curve and to a kit for peripherin determination.

The present application relates to the technical field of biosensing detection and natural product drug discovery, and particularly relates to a multi-target vertical fishing screening and recovery identification method for target discovery of natural products or traditional Chinese medicine extracts. The method comprises the following steps: constructing a target panel related to a target disease or biological process, and fixing at least two different decoy molecules in the panel to different channels of a bio-layer interferometry (BLI) sensor array respectively, while at least one reference channel is set; placing the sensor array in the same portion of a natural product or traditional Chinese medicine extract solution to be tested, and collecting the binding / dissociation kinetics curves in parallel; performing reference deduction, drift correction and normalization processing on the data of each channel; discriminating the corrected curves according to a preset kinetics gating criterion, outputting the decoy channel set passing the gating, and generating a confidence score to form a Top-N candidate target list; cleaning and micro-eluting the sensor surface of the candidate channel, and performing mass spectrometry, sequencing or immunology and other downstream identification on the elution recovery to establish a correspondence between the target and the binding molecule.

本发明属于生物医学检测技术领域，具体涉及一种定量检测HBV preS2蛋白并鉴定血清亚型的方法。包括：采用LC‑MS / MS采集各亚型preS2蛋白特异性离子对信号；以标准曲线结合内标校正计算蛋白含量；同时提取血清HBV DNA，对preS2区进行PCR扩增和测序，与已知亚型参考序列比对确认亚型归属。本发明检测下限达100 pg / mL，可同时区分adw、adr、adr‑m、ayw、ayr五种亚型。在HBsAg阴性的隐匿性乙型肝炎患者中，该方法的preS2蛋白检出率达60%；在功能性治愈患者中，preS2蛋白检出率达70%。本发明通过质谱定量与核酸测序双重验证，为HBV特殊人群提供了可靠检测手段。

This invention relates to the field of medical electro-digital data processing, and discloses a decision-making system for detecting melting curves of gene polymorphisms in hypertension medication. It collects fluorescence melting curve data of multiple gene targets; maps the melting temperature-fluorescence intensity derivative curve as graph structure nodes, and maps the melting feature associations between different gene loci as edges, constructing a multidimensional melting curve topology graph; extracts the co-fluctuation features of node peak temperature offset and edge weights and inputs them into a graph convolutional network, outputting a polymorphic combination feature vector; maps the polymorphic combination feature vector to a hypertension drug metabolism network graph model, calculates the joint decay coefficient of drug metabolic enzyme activity and receptor binding rate, and determines the type and dosage adjustment parameters for hypertension medication based on the joint decay coefficient. This invention overcomes the deficiency of single-peak independent alignment in separating overlapping peaks, achieves quantitative analysis of co-fluctuation associations of multi-gene polymorphisms, and eliminates medication bias caused by isolated qualitative matching.